Overview

The Insulin-Only Bionic Pancreas Bridging Study

Status:
Completed
Trial end date:
2018-11-19
Target enrollment:
Participant gender:
Summary
The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas. The iLet consists of a touchscreen-enabled, menu-driven user interface and an onboard microprocessor that provides a comprehensive and standalone platform, which allows the iLet to operate independently of smartphones or other devices and without the need for internet support during routine operation. This is a multicenter study of adult participants with type 1 diabetes, who will manage their diabetes with the iLet bionic pancreas compared to usual care.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin Lispro
Insulin, Globin Zinc
Insulin, Long-Acting
Pancreatin
Pancrelipase